Yoonjeong Cha

Statistics

Publications

Citations

435

H-Index

Active since

2016

Affiliations

Immuneering (United States)(Current)

Teva Pharmaceuticals (Israel)

National University of Singapore

Child and Family Research Institute

Agency for Science, Technology and Research

Yoonjeong Cha is an author at Immuneering (United States) specializing in pharmacology, huntington disease neuroprotection, and neurodegenerative disorders.

ORCID

Publications per year

2016–2020

Publications

Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors

Xiumei Huang, Edward A. Motea, Zachary Moore et al. · Cancer Cell · 2016 · 132 citations · Full text

Medicine, Oncology, Pharmacology +12

Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)

Jason Kim, Jenny Zhang, Yoonjeong Cha et al. · Journal of Translational Medicine · 2020 · 90 citations · Full text

Pharmacy, Bioinformatics, Pharmacology +15

Pridopidine activates neuroprotective pathways impaired in Huntington Disease

Michal Geva, Rebecca Kusko, Holly Soares et al. · Human Molecular Genetics · 2016 · 79 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice

Marta Garcia‐Miralles, Michal Geva, Jing Tan et al. · JCI Insight · 2017 · 45 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse

Rebecca Kusko, Jennifer Dreymann, Jermaine Ross et al. · Molecular Neurodegeneration · 2018 · 44 citations · Full text

Medicine, Neurology, Neuroscience +17

1–5 of 7